Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.

Kidokoro M, Tashiro M, Shida H.

Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4152-7. Epub 2005 Mar 7.

2.

An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.

Morikawa S, Sakiyama T, Hasegawa H, Saijo M, Maeda A, Kurane I, Maeno G, Kimura J, Hirama C, Yoshida T, Asahi-Ozaki Y, Sata T, Kurata T, Kojima A.

J Virol. 2005 Sep;79(18):11873-91.

3.

LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox.

Saijo M, Ami Y, Suzaki Y, Nagata N, Iwata N, Hasegawa H, Ogata M, Fukushi S, Mizutani T, Sata T, Kurata T, Kurane I, Morikawa S.

J Virol. 2006 Jun;80(11):5179-88.

4.

Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice.

Yokote H, Shinmura Y, Kanehara T, Maruno S, Kuranaga M, Matsui H, Hashizume S.

Vaccine. 2015 Nov 9;33(45):6112-9. doi: 10.1016/j.vaccine.2015.07.076. Epub 2015 Aug 1.

5.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

6.

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.

7.

Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Meseda CA, Mayer AE, Kumar A, Garcia AD, Campbell J, Listrani P, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Clin Vaccine Immunol. 2009 Sep;16(9):1261-71. doi: 10.1128/CVI.00040-09. Epub 2009 Jul 15.

8.

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Wyatt LS, Earl PL, Eller LA, Moss B.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5. Epub 2004 Mar 11.

9.

Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.

Dimier J, Ferrier-Rembert A, Pradeau-Aubreton K, Hebben M, Spehner D, Favier AL, Gratier D, Garin D, Crance JM, Drillien R.

J Virol. 2011 May;85(10):5016-26. doi: 10.1128/JVI.02359-10. Epub 2011 Mar 2.

10.

Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.

Empig C, Kenner JR, Perret-Gentil M, Youree BE, Bell E, Chen A, Gurwith M, Higgins K, Lock M, Rice AD, Schriewer J, Sinangil F, White E, Buller RM, Dermody TS, Isaacs SN, Moyer RW.

Vaccine. 2006 Apr 24;24(17):3686-94.

PMID:
16430997
11.

Characterization of a vaccinia virus strain used to produce smallpox vaccine in Argentina between 1937 and 1970.

Lewis A, Bok K, Perez O, DeFillippo J, Paolazzi C, Gomez JA.

Arch Virol. 2005 Jul;150(7):1485-91. Epub 2005 Mar 8.

PMID:
15750861
12.

Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, Lock M, Empig C, Morikawa S, Saijo M, Yokote H, Karem K, Damon I, Perlroth M, Greenberg RN.

J Infect Dis. 2011 Nov;204(9):1395-402. doi: 10.1093/infdis/jir527. Epub 2011 Sep 15.

13.

The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.

Coulibaly S, Brühl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG.

Virology. 2005 Oct 10;341(1):91-101.

14.

Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.

Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH.

J Virol. 2008 Jul;82(14):6829-37. doi: 10.1128/JVI.00353-08. Epub 2008 Apr 30.

15.

Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain.

Bissa M, Pacchioni SM, Zanotto C, De Giuli Morghen C, Illiano E, Granucci F, Zanoni I, Broggi A, Radaelli A.

Virus Res. 2013 Dec 26;178(2):374-82. doi: 10.1016/j.virusres.2013.09.016. Epub 2013 Sep 16.

PMID:
24050999
16.

Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.

Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, Oh SK.

J Virol. 2007 Aug;81(16):8774-83. Epub 2007 Jun 6.

17.

Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene.

Laassri M, Meseda CA, Williams O, Merchlinsky M, Weir JP, Chumakov K.

J Med Virol. 2007 Jun;79(6):791-802.

PMID:
17457926
18.

Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.

Ober BT, Brühl P, Schmidt M, Wieser V, Gritschenberger W, Coulibaly S, Savidis-Dacho H, Gerencer M, Falkner FG.

J Virol. 2002 Aug;76(15):7713-23.

19.

Safety of attenuated smallpox vaccine LC16m8 in immunodeficient mice.

Yokote H, Shinmura Y, Kanehara T, Maruno S, Kuranaga M, Matsui H, Hashizume S.

Clin Vaccine Immunol. 2014 Sep;21(9):1261-6. doi: 10.1128/CVI.00199-14. Epub 2014 Jul 2.

20.

Supplemental Content

Support Center